IV
Innovent Biologics, Inc.
IVBXF · OTC
$12.36 +12.27% (+$1.35)
1M +4.75%
Market Cap ¥144.0B
P/E Ratio 181.74x
Div. Yield -
ROE 4.69%
Bulios Fair Price
$11.28
8.7% downside
Current Price
$12.36
Undervalued Fair Value Overvalued
According to Bulios Fair Price, IVBXF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
25 /100
Expensive P/E 181.74x
EV/EBITDA 65.76x
P/FCF 15.46x
Growth
100 /100
Growing Rev. growth 40.75%
Book val. growth 21.75%
EPS growth N/A
Profitability
79 /100
Strong Gross margin 86.54%
Net margin 6.24%
FCF margin 73.34%
Quality
27 /100
Poor ROIC 6.59%
ROE 4.69%
Asset turnover 0.34x
Debt
100 /100
Low Debt/Equity 0.15x
Current ratio 2.62x
Net debt/EBITDA -7.38x
Stability
34 /100
Moderate Beta 0.24x
Rev. volatility 9.43%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about IVBXF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
De-Chao Yu
Employees
7,502
Headquarters
Suzhou
Upcoming events
31 MAR
Earnings
Upcoming earnings report